Bluebird, at risk of default, agrees to take-private deal
Bio Pharma Dive
FEBRUARY 21, 2025
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth years ago.
Fri.Feb 21, 2025
306 
Pfizer shelves haemophilia gene therapy Beqvez amid low demand
Pharmaceutical Technology
FEBRUARY 21, 2025
Pfizer said resources will be directed to its other haemophilia gene therapy Hympavzi.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair
Bio Pharma Dive
FEBRUARY 21, 2025
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.
Creative Biolabs Continues Partnering with Pharmaceutical Corporations to Drive Biopharmaceutical Innovation for 2025 and Beyond
Pharma Mirror
FEBRUARY 21, 2025
As a provider of custom services, Creative Biolabs aims to support the entire process of drug discovery and development for the global pharmaceutical industry using its cutting-edge technology and wide-ranging experiences. It is no secret that the complexities associated with biopharmaceuticals are ever increasing, particularly regarding the development of antibody therapeutics.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Stealth virus: How Zika builds tunnels to covertly infect cells of the placenta
Medical Xpress
FEBRUARY 21, 2025
Infection with Zika virus in pregnancy can lead to neurological disorders, fetal abnormalities and fetal death. Until now, how the virus manages to cross the placenta, which nurtures the developing fetus and forms a strong barrier against microbes and chemicals that could harm the fetus, has not been clear. Researchers at Baylor College of Medicine with collaborators at Pennsylvania State University report in Nature Communications a strategy Zika virus uses to covertly spread in placental cells,
Pfizer stops selling hemophilia gene therapy, citing weak demand
Bio Pharma Dive
FEBRUARY 21, 2025
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Pharmaceutical Technology
FEBRUARY 21, 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.
Aardvark Therapeutics IPO Sets Sights on Satiating Hyperphagia and Extreme Hunger
XTalks
FEBRUARY 21, 2025
Aardvark Therapeutics, Inc. has priced its initial public offering (IPO) at $16.00 per share, offering 5,888,000 shares and targeting approximately $94.2 million in gross proceeds. Trading on Nasdaq under the ticker AARD began on February 13, 2025. This capital will accelerate the companys clinical programs and support its pipeline of investigational drugs aimed at treatments for metabolic diseases like Prader-Willi syndrome (PWS).
Struggling bluebird bio to go private for less than $30m
Pharmaceutical Technology
FEBRUARY 21, 2025
Bluebird has faced financial pressures over the last few years, leading to several restructuring efforts.
The Role of Diagnostics in Advancing Antibody-Drug Conjugates
XTalks
FEBRUARY 21, 2025
Antibody-drug conjugates (ADCs) have emerged as one of the most promising advancements in precision oncology, combining targeted delivery with the potency of traditional chemotherapies. Over the last decade, ADCs have gained significant traction, with more therapies being approved and a rapidly expanding development pipeline. While the therapeutic promise of ADCs is clear, success in this space depends on more than just the drug itself it relies heavily on precise and reliable diagnostic testin
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
UroGen acquires IconOVir’s oncolytic virus assets
Pharmaceutical Technology
FEBRUARY 21, 2025
UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bios assets related to the oncolytic virus ICVB-1042.
A stressed mind is made more prone to rigid thinking, mouse study finds
Medical Xpress
FEBRUARY 21, 2025
University of California, Los Angeles researchers have discovered that chronic stress flips brain activity between two amygdala-striatal pathways, disrupting flexible decision-making and promoting inflexible habits.
Incyte and Genesis collaborate on small-molecule medicines
Pharmaceutical Technology
FEBRUARY 21, 2025
Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule medicines.
Poolbeg slumps as Hookipa merger is called off
pharmaphorum
FEBRUARY 21, 2025
A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.
NICE green lights two blood cancer therapies for NHS use
Pharmaceutical Technology
FEBRUARY 21, 2025
BMS' Breyanzi and Amgens Blincyto will now be available to patients in England with certain types of blood cancer.
From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN
Drug Channels
FEBRUARY 21, 2025
Today's guest post comes from Thomas Luby, Sr. Vice President, Business Development at PHIL. Thomas discusses the challenges brands face as they manage gross-to-net (GTN) performance while simultaneously enhancing patient access and adherence. He lists the key performance indicators that can help brands improve GTN. To learn more, watch PHILs free on-demand webinar: Four Patient Access Barriers to Address for High-Impact Programs.
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
Pharmaceutical Technology
FEBRUARY 21, 2025
CSL Behring KK has gained approval from Japan's MHLW to manufacture and market subcutaneous injection 200mg Andembry pens.
Language barriers in health care: Patient-doctor common tongue key to decreasing cardiovascular disease and longer life
Medical Xpress
FEBRUARY 21, 2025
A positive patient-doctor relationship is an ingredient to a healthy life, and new research has zeroed in on the impact common language in the relationship can have by decreasing cardiovascular disease for the benefit of a longer life.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Navigating the Complexities of Sustainable Specialty Pharma Supply Chains
Pharmaceutical Technology
FEBRUARY 21, 2025
How can pharmaceutical firms shore up their sustainability credentials at a time when the entire research landscape is turning on its head?
Cell therapies are the future of healthcare, why are we struggling to make them at scale?
pharmaphorum
FEBRUARY 21, 2025
Cell therapies show great promise for revolutionising healthcare, but challenges remain in scaling up production. Learn more about the current obstacles and potential solutions in this informative article.
How CNS researchers are handling clinical trial turbulence
Pharmaceutical Technology
FEBRUARY 21, 2025
The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are opening up.
Novel PET tracer reveals potential for recovery in spinal cord injuries
Medical Xpress
FEBRUARY 21, 2025
A novel PET technique that visualizes spinal cord injuries provides critical information about which patients may be able to regain mobility, according to new research published in the February issue of The Journal of Nuclear Medicine. By detecting intact nerve connections in the injured spinal cord, a newly developed radiotracer has the potential to help diagnose injuries more precisely, monitor recovery, and evaluate the effectiveness of new therapies in clinical trials.
AstraZeneca builds in China as Cosette buys Mayne
pharmaphorum
FEBRUARY 21, 2025
The reporting week has ended with a flurry of M&A as Cosette Pharma and AstraZeneca agree takeover deals
Plant-rich, low saturated-fat diet associated with reduced psoriasis severity
Medical Xpress
FEBRUARY 21, 2025
A diet of fruits and vegetables, whole grains, low-fat dairy foods and lean meats, low in salt and sugar, is associated with reduced psoriasis severity, new research finds.
The Biosimilars Landscape Through the Eyes of an Economist
Pharmaceutical Commerce
FEBRUARY 21, 2025
James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.
Islet transplantation with blood vessel cells shows promise to treat type 1 diabetes
Medical Xpress
FEBRUARY 21, 2025
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. The new approach, which requires further development and testing, could someday enable the much wider use of islet transplants to cure diabetes.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharma and Biotech Layoffs 2025
XTalks
FEBRUARY 21, 2025
Waves of targeted job cuts are continuing into 2025 across pharma and biotech as companies respond to pipeline setbacks, patent cliffs and shifting regulatory landscapes. Reductions to workforces are being propelled by financial pressures and strategic realignments, as companies grapple with revenue losses from patent expirations and decide to redirect their focus.
Higher calcium intake linked to reduced colorectal cancer risk
Medical Xpress
FEBRUARY 21, 2025
Higher calcium intake is associated with reduced colorectal cancer (CRC) risk across tumor sites and calcium sources, according to a study published online Feb. 17 in JAMA Network Open.
Trial of Boehringer's cystic fibrosis gene therapy imminent
pharmaphorum
FEBRUARY 21, 2025
Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping to offer a one-shot alternative to costly CFTR modulator drugs.
Vaccine shows promise for pancreatic cancer, study finds
Medical Xpress
FEBRUARY 21, 2025
Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet promising study from Memorial Sloan Kettering Cancer Center.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Let's personalize your content